ANTIBODY-INDEPENDENT ANTITUMOR EFFECTS OF CD32A-CHIMERIC RECEPTOR T CELLS: IMPLICATIONS FOR BREAST CANCER PROGNOSIS AND TREATMENT.
G. Sconocchia, G. Lanzilli, V. Cesarini, D. A. Sivestris, R. Arriga, K. Rezvani, S. Caratelli, K. Chen, J. Dou, C. Cenciarelli, G. Toietta, S. Baldari, T. Sconocchia, F. De Paolis, A. Aureli, , G. C. Spagnoli
This study shows CD32A-chimeric receptor T cells can identify CD32A ligands, predict breast cancer sensitivity, and improve prognosis without antibodies.
bioRxiv · Dec 22, 2021 · PreprintImmunology